Pharmacokinetic Study of Adenosine Diphosphate-Encapsulated Liposomes Coated with Fibrinogen γ-Chain Dodecapeptide as a Synthetic Platelet Substitute in an Anticancer Drug-Induced Thrombocytopenia Rat Model

Kazuaki Taguchi, Hayato Ujihira, Hiroshi Watanabe, Atsushi Fujiyama, Mami Doi, Shinji Takeoka, Yasuo Ikeda, Makoto Handa, Masaki Otagiri, Toru Maruyama

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A fibrinogen γ-chain (dodecapeptide HHLGGAKQAGDV, H12)-coated, adenosine diphosphate (ADP)-encapsulated liposome [H12-(ADP)-liposome] was designed to achieve optimal performance as a homeostatic agent and expected as a synthetic platelet alternative. For the purpose of efficient function as platelet substitute, H12-(ADP)-liposomes should potentially have both acceptable pharmacokinetic and biodegradable properties under conditions of an adaptation disease including thrombocytopenia induced by anticancer drugs. The aim of this study was to characterize the pharmacokinetics of H12-(ADP)-liposomes in busulphan-induced thrombocytopenic rats using 14C, 3H double radiolabeled H12-(ADP)-liposomes, in which the encapsulated ADP and liposomal membrane (cholesterol) were labeled with 14C and 3H, respectively. After the administration of H12-(ADP)-liposomes, they were determined to be mainly distributed to the liver and spleen and disappeared from organs within 7 days after injection. The encapsulated ADP was mainly eliminated in the urine, whereas the outer membrane (cholesterol) was mainly eliminated in feces. The successive dispositions of the H12-(ADP)-liposomes were similar in both normal and thrombocytopenic rats. However, the kinetics of H12-(ADP)-liposomes in thrombocytopenic rats was more rapid, compared with the corresponding values for normal rats. These findings, which well reflect the clinical features of patients with anticancer drug-induced thrombocytopenia, provide useful information for the development of the H12-(ADP)-liposomes for future clinical use.

Original languageEnglish
Pages (from-to)3852-3859
Number of pages8
JournalJournal of Pharmaceutical Sciences
Volume102
Issue number10
DOIs
Publication statusPublished - 2013 Oct

Fingerprint

Liposomes
Thrombocytopenia
Adenosine Diphosphate
Fibrinogen
Blood Platelets
Pharmacokinetics
Pharmaceutical Preparations
Cholesterol
Busulfan
Membranes
Feces
Reference Values
Spleen
Urine
Injections
Liver

Keywords

  • Adenosine-diphosphate
  • Biocompatibility
  • Cancer chemothrapy
  • Disease state
  • Disposition
  • Dodecapeptide
  • Liposome
  • Platelet substitute
  • Thrombocytopenia

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Pharmacokinetic Study of Adenosine Diphosphate-Encapsulated Liposomes Coated with Fibrinogen γ-Chain Dodecapeptide as a Synthetic Platelet Substitute in an Anticancer Drug-Induced Thrombocytopenia Rat Model. / Taguchi, Kazuaki; Ujihira, Hayato; Watanabe, Hiroshi; Fujiyama, Atsushi; Doi, Mami; Takeoka, Shinji; Ikeda, Yasuo; Handa, Makoto; Otagiri, Masaki; Maruyama, Toru.

In: Journal of Pharmaceutical Sciences, Vol. 102, No. 10, 10.2013, p. 3852-3859.

Research output: Contribution to journalArticle

Taguchi, Kazuaki ; Ujihira, Hayato ; Watanabe, Hiroshi ; Fujiyama, Atsushi ; Doi, Mami ; Takeoka, Shinji ; Ikeda, Yasuo ; Handa, Makoto ; Otagiri, Masaki ; Maruyama, Toru. / Pharmacokinetic Study of Adenosine Diphosphate-Encapsulated Liposomes Coated with Fibrinogen γ-Chain Dodecapeptide as a Synthetic Platelet Substitute in an Anticancer Drug-Induced Thrombocytopenia Rat Model. In: Journal of Pharmaceutical Sciences. 2013 ; Vol. 102, No. 10. pp. 3852-3859.
@article{f3f4273365f74511b8c41047db6ef3c1,
title = "Pharmacokinetic Study of Adenosine Diphosphate-Encapsulated Liposomes Coated with Fibrinogen γ-Chain Dodecapeptide as a Synthetic Platelet Substitute in an Anticancer Drug-Induced Thrombocytopenia Rat Model",
abstract = "A fibrinogen γ-chain (dodecapeptide HHLGGAKQAGDV, H12)-coated, adenosine diphosphate (ADP)-encapsulated liposome [H12-(ADP)-liposome] was designed to achieve optimal performance as a homeostatic agent and expected as a synthetic platelet alternative. For the purpose of efficient function as platelet substitute, H12-(ADP)-liposomes should potentially have both acceptable pharmacokinetic and biodegradable properties under conditions of an adaptation disease including thrombocytopenia induced by anticancer drugs. The aim of this study was to characterize the pharmacokinetics of H12-(ADP)-liposomes in busulphan-induced thrombocytopenic rats using 14C, 3H double radiolabeled H12-(ADP)-liposomes, in which the encapsulated ADP and liposomal membrane (cholesterol) were labeled with 14C and 3H, respectively. After the administration of H12-(ADP)-liposomes, they were determined to be mainly distributed to the liver and spleen and disappeared from organs within 7 days after injection. The encapsulated ADP was mainly eliminated in the urine, whereas the outer membrane (cholesterol) was mainly eliminated in feces. The successive dispositions of the H12-(ADP)-liposomes were similar in both normal and thrombocytopenic rats. However, the kinetics of H12-(ADP)-liposomes in thrombocytopenic rats was more rapid, compared with the corresponding values for normal rats. These findings, which well reflect the clinical features of patients with anticancer drug-induced thrombocytopenia, provide useful information for the development of the H12-(ADP)-liposomes for future clinical use.",
keywords = "Adenosine-diphosphate, Biocompatibility, Cancer chemothrapy, Disease state, Disposition, Dodecapeptide, Liposome, Platelet substitute, Thrombocytopenia",
author = "Kazuaki Taguchi and Hayato Ujihira and Hiroshi Watanabe and Atsushi Fujiyama and Mami Doi and Shinji Takeoka and Yasuo Ikeda and Makoto Handa and Masaki Otagiri and Toru Maruyama",
year = "2013",
month = "10",
doi = "10.1002/jps.23692",
language = "English",
volume = "102",
pages = "3852--3859",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Pharmacokinetic Study of Adenosine Diphosphate-Encapsulated Liposomes Coated with Fibrinogen γ-Chain Dodecapeptide as a Synthetic Platelet Substitute in an Anticancer Drug-Induced Thrombocytopenia Rat Model

AU - Taguchi, Kazuaki

AU - Ujihira, Hayato

AU - Watanabe, Hiroshi

AU - Fujiyama, Atsushi

AU - Doi, Mami

AU - Takeoka, Shinji

AU - Ikeda, Yasuo

AU - Handa, Makoto

AU - Otagiri, Masaki

AU - Maruyama, Toru

PY - 2013/10

Y1 - 2013/10

N2 - A fibrinogen γ-chain (dodecapeptide HHLGGAKQAGDV, H12)-coated, adenosine diphosphate (ADP)-encapsulated liposome [H12-(ADP)-liposome] was designed to achieve optimal performance as a homeostatic agent and expected as a synthetic platelet alternative. For the purpose of efficient function as platelet substitute, H12-(ADP)-liposomes should potentially have both acceptable pharmacokinetic and biodegradable properties under conditions of an adaptation disease including thrombocytopenia induced by anticancer drugs. The aim of this study was to characterize the pharmacokinetics of H12-(ADP)-liposomes in busulphan-induced thrombocytopenic rats using 14C, 3H double radiolabeled H12-(ADP)-liposomes, in which the encapsulated ADP and liposomal membrane (cholesterol) were labeled with 14C and 3H, respectively. After the administration of H12-(ADP)-liposomes, they were determined to be mainly distributed to the liver and spleen and disappeared from organs within 7 days after injection. The encapsulated ADP was mainly eliminated in the urine, whereas the outer membrane (cholesterol) was mainly eliminated in feces. The successive dispositions of the H12-(ADP)-liposomes were similar in both normal and thrombocytopenic rats. However, the kinetics of H12-(ADP)-liposomes in thrombocytopenic rats was more rapid, compared with the corresponding values for normal rats. These findings, which well reflect the clinical features of patients with anticancer drug-induced thrombocytopenia, provide useful information for the development of the H12-(ADP)-liposomes for future clinical use.

AB - A fibrinogen γ-chain (dodecapeptide HHLGGAKQAGDV, H12)-coated, adenosine diphosphate (ADP)-encapsulated liposome [H12-(ADP)-liposome] was designed to achieve optimal performance as a homeostatic agent and expected as a synthetic platelet alternative. For the purpose of efficient function as platelet substitute, H12-(ADP)-liposomes should potentially have both acceptable pharmacokinetic and biodegradable properties under conditions of an adaptation disease including thrombocytopenia induced by anticancer drugs. The aim of this study was to characterize the pharmacokinetics of H12-(ADP)-liposomes in busulphan-induced thrombocytopenic rats using 14C, 3H double radiolabeled H12-(ADP)-liposomes, in which the encapsulated ADP and liposomal membrane (cholesterol) were labeled with 14C and 3H, respectively. After the administration of H12-(ADP)-liposomes, they were determined to be mainly distributed to the liver and spleen and disappeared from organs within 7 days after injection. The encapsulated ADP was mainly eliminated in the urine, whereas the outer membrane (cholesterol) was mainly eliminated in feces. The successive dispositions of the H12-(ADP)-liposomes were similar in both normal and thrombocytopenic rats. However, the kinetics of H12-(ADP)-liposomes in thrombocytopenic rats was more rapid, compared with the corresponding values for normal rats. These findings, which well reflect the clinical features of patients with anticancer drug-induced thrombocytopenia, provide useful information for the development of the H12-(ADP)-liposomes for future clinical use.

KW - Adenosine-diphosphate

KW - Biocompatibility

KW - Cancer chemothrapy

KW - Disease state

KW - Disposition

KW - Dodecapeptide

KW - Liposome

KW - Platelet substitute

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=84883781046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883781046&partnerID=8YFLogxK

U2 - 10.1002/jps.23692

DO - 10.1002/jps.23692

M3 - Article

VL - 102

SP - 3852

EP - 3859

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 10

ER -